Valbenazine(Ingrezza, Mt-5199, NBI-98854, VBZ) is a potent inhibitor of vesicular monoamine transporter 2 (VMAT2) with a Ki of 110–190 nM. It is used to treat tardive dyskinesia and chorea associated with Huntington’s disease.

Vardenafil dihydrochloride is a potent, and selective inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. It also exhibits inhibition of PDE1 and PDE6 with IC50 of 180 nM and 11 nM respectively. It can be used for the research of erectile dysfunction, hepatitis, diabetes.

Vardenafil dihydrochloride is a potent, and selective inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. It also exhibits inhibition of PDE1 and PDE6 with IC50 of 180 nM and 11 nM respectively. It can be used for the research of erectile dysfunction, hepatitis, diabetes.

Valbenazine(Ingrezza, Mt-5199, NBI-98854, VBZ) is a potent inhibitor of vesicular monoamine transporter 2 (VMAT2) with a Ki of 110–190 nM. It is used to treat tardive dyskinesia and chorea associated with Huntington’s disease.

Vilanterol (GW642444) is a potent and selective agonist of β2-adrenoceptor (β2-AR) with pEC50 of β2-AR, β1-AR, and β3-AR is 10.37, 6.98 and 7.36 respectively in cAMP detection assays.

Vilanterol (GW642444) is a potent and selective agonist of β2-adrenoceptor (β2-AR) with pEC50 of β2-AR, β1-AR, and β3-AR is 10.37, 6.98 and 7.36 respectively in cAMP detection assays.

Vilanterol (GW642444) is a potent and selective agonist of β2-adrenoceptor (β2-AR) with pEC50 of β2-AR, β1-AR, and β3-AR is 10.37, 6.98 and 7.36 respectively in cAMP detection assays.

Vorapaxar sulfate (SCH 530348 sulfate) is a selective and orally active antagonist of protease-activated receptor (PAR-1), with a Ki value of 8.1 nM. Vorapaxar sulfate reduces thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner.

Vilanterol (GW642444) is a potent and selective agonist of β2-adrenoceptor (β2-AR) with pEC50 of β2-AR, β1-AR, and β3-AR is 10.37, 6.98 and 7.36 respectively in cAMP detection assays.

Vorapaxar sulfate (SCH 530348 sulfate) is a selective and orally active antagonist of protease-activated receptor (PAR-1), with a Ki value of 8.1 nM. Vorapaxar sulfate reduces thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner.